Author:
Xu Wenhao,Tian Xi,Liu Wangrui,Anwaier Aihetaimujiang,Su Jiaqi,Zhu Wenkai,Wan Fangning,Shi Guohai,Wei Gaomeng,Qu Yuanyuan,Zhang Hailiang,Ye Dingwei
Abstract
BackgroundThis study aims to establish an N6-methyladenosine (m6A) RNA methylation regulators-mediated methylation model and explore its role in predicting prognostic accuracy of immune contexture and characterizations of clear cell renal cell carcinoma (ccRCC).MethodsThe m6A modification subclasses (m6AMS) were identified by unsupervised cluster analysis and three clusters were determined by consensus clustering algorithm in a discovering cohort. Testing and real-world validation cohorts were used to identify predictive responses for immune checkpoint therapies (ICTs) of m6AMS.ResultsPrognostic implications landscape of m6A regulators in cancers and its differential expression levels in ccRCC patients were identified. Based on discovering cohort, ccRCC were automatically divided into three m6AMS, and cluster 3 showed significant worse survival than cluster 1/2. Importantly, it was found that the immune checkpoint molecules expression was significantly elevated in cluster 3. Besides, m6A scoreLow group (cluster 1&2) have significantly elevated TIDE score compared with m6A scoreHigh group (cluster 3). There was conspicuous tertiary lymphoid tissue, aggressive phenotype, elevated glycolysis, expression of PD-L1, abundance of CD8+ T cells, CD4+ FOXP3+ Treg cells and TCRn immune cells infiltration in the high m6A score group. Interestingly, there are significantly increased patients with clinical benefit in m6A scoreHigh group in 368 patients receiving ICTs from testing IMvigor210 (n = 292) and validation FUSCC (n = 55) cohorts.ConclusionOur discovery highlights the relationship between tumor epigenetic heterogeneity and immune contexture. Immune-rejection cluster 3 has pro-tumorigenic immune infiltration, and shows significant clinical benefits for ccRCC patients receiving ICTs, enabling patient selection for future clinical treatment.
Funder
National Key Research and Development Program of China
Natural Science Foundation of Shanghai
Shanghai Municipal Health Bureau
Reference47 articles.
1. Cancer Statistics, 2020;Siegel;CA Cancer J Clin,2020
2. Renal Cancer;Capitanio;Lancet,2016
3. Systemic Therapy for Metastatic Renal-Cell Carcinoma;Choueiri;N Engl J Med,2017
4. Comprehensive Molecular Characterization of Clear Cell Renal Cell Carcinoma;Cancer Genome Atlas Research;Nature,2013
5. Identification and Validation of Novel Metastasis-Related Signatures of Clear Cell Renal Cell Carcinoma Using Gene Expression Databases;Ma;Am J Transl Res,2020
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献